Datapoint: Regeneron Scores NSCLC Win for Libtayo

The FDA last week approved Regeneron Pharmaceuticals, Inc.’s Libtayo in newly diagnosed non-small cell lung cancer (NSCLC). The nod positions Libtayo to directly challenge Merck’s Keytruda, the only other PD-1/L1 inhibitor approved for NSCLC in combination with chemotherapy regardless of PD-L1 expression or histology. As a systemic therapy for NSCLC, Keytruda currently holds covered or better status for 65% of insured lives under the pharmacy benefit. Meanwhile, 86% of insured lives have covered or better access to Keytruda for NSCLC under the medical benefit.

SOURCE: MMIT Analytics, as of 11/9/22

0 Comments
AIS Health Staff

AIS Health Staff

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
November 23

Datapoint: Apellis Gets Updated Review Date for Eye Blockbuster Hopeful

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
November 22

Datapoint: Regence Sees 95% Biosimilar Adoption

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
November 17

Datapoint: Sanford, Fairview Health Announce Merger

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today